Pharmaceutical

ImPact enters partnership for pathologic myopia therapy development

ImPact Biotech entered into a partnership with Maastricht University to develop a therapy for arresting pathologic myopia progression.

Aug 14, 2023 - 20:00
ImPact enters partnership for pathologic myopia therapy development
ImPact Biotech entered into a partnership with Maastricht University to develop a therapy for arresting pathologic myopia progression.
Read the original article

Tags:

Previous Article

RNA-LNPs: Navigating the regulatory challenges

Next Article

Biopharma firm Zetagen raises $9.79m in Series B financing round

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: With Menendez indictment, pharmaceutical industry could lose a key ally

STAT+: With Menendez indictment, pharmaceutical industr...

Sep 26, 2023

STAT+: Drug companies and pharmacies reach $17.3 billion settlement over opioid crisis

STAT+: Drug companies and pharmacies reach $17.3 billio...

Jun 10, 2023

Genentech buys Regor’s CDK inhibitors in $850m deal 

Genentech buys Regor’s CDK inhibitors in $850m deal 

Oct 2, 2024